Recruiting
Phase 1

pTVG-HP & Nivolumab

Sponsor:

University of Wisconsin, Madison

Code:

NCT07090148

Conditions

Prostate Cancer Patients

Non-castrate Prostate Cancer

Recurrent Prostate Cancer

Oligometastatic Prostate Cancer (OMPC)

Eligibility Criteria

Sex: Male

Age: 18+

Healthy Volunteers: Not accepted

Interventions

pTVG-HP DNA vaccine

Anti-PD-1 monoclonal antibody

Study Details

Brief summary:

The goal of this clinical trial is to learn whether an experimental vaccine called pTVG-HP ("vaccine" or "DNA vaccine"), combined with a drug called nivolumab can increase the cancer-fighting ability of a person's immune cells.

The main question it aims to answer is whether the combination of medicines can get rid of metastatic tumors in participants with non-castrate, recurrent, oligometastatic prostate cancer.

Participants will undergo:

  • Treatment with pTVG-HP
  • Treatment with Nivolumab
  • Radiation Therapy

Conditions

Prostate Cancer Patients

Non-castrate Prostate Cancer

Recurrent Prostate Cancer

Oligometastatic Prostate Cancer (OMPC)

Study ID

NCT07090148

Start date

Mar 3, 2026

Status verified date

Mar, 2026

Completion date

Oct, 2030

Anticipated

Primary completion date

Oct, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Male

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Participants must be at least 18 years of age with a histologic diagnosis of adenocarcinoma of the prostate
  • Participants must have undergone radical prostatectomy
  • Participants must have completed local therapy by surgery, and any adjuvant/salvage radiation therapy (if required), at least 3 months prior to entry, with removal or ablation of all visible disease, including seminal vesical and/or local lymph node involvement.
  • Participants must have biochemically recurrent disease defined by the following:

  • PSA doubling time, calculated from most recent 4 serum PSA values (collected up to one year prior to enrollment, at least 2 weeks apart, and all from the same clinical laboratory), must be a positive number (i.e. evidence of PSA rise over time).
  • Participants must have oligometastatic disease, defined as:

  • < 3 lesions consistent with metastases as detected by CT of the abdomen/pelvis and bone scintigraphy (bone scan)
  • Lesions consistent with metastatic prostate cancer as detected by PSMA PET/CT
  • Participants with a prior history of a second malignancy are eligible provided they have been treated with curative intent and have been free of disease greater than three years. There will be no exclusion for patients with a history of basal cell carcinoma, squamous cell skin cancer, superficial bladder cancer, or other in situ carcinoma that has been adequately treated.
  • Participants who are sexually active must use a reliable form of contraception while on study and for 4 weeks after the last immunization.
  • ECOG performance score < 2 and life expectancy of at least 12 months.
  • Participants must have normal hematologic, renal and liver function
  • Participants must be informed of the experimental nature of the study and its potential risks and must sign an IRB-approved written informed consent form indicating such an understanding.
  • Willingness to provide blood samples for immune studies, per study calendar, up to one year after study, even if off treatment.

Exclusion Criteria:

  • Small cell or other variant prostate cancer histology
  • Participants cannot have evidence of immunosuppression or have been treated with immunosuppressive therapy, such as chemotherapy or chronic treatment dose corticosteroids (greater than the equivalent of 10 mg prednisone per day), within 3 months of the first vaccination.
  • Seropositive for HIV, hepatitis B (HBV) or hepatitis C (HCV) per patient history due to the immunosuppressive features of these diseases.
  • Prior treatment with an LHRH agonist or nonsteroidal antiandrogen, except in the following circumstances: Neoadjuvant/adjuvant androgen deprivation therapy administered with radiation therapy or at the time of prostatectomy is acceptable, provided that there was no evidence of PSA progression while on treatment. In this situation, patients must not have received more than 24 months of androgen deprivation treatment. Other treatment with androgen deprivation therapy is prohibited.
  • Serum testosterone at screening < 50 ng/dL.
  • Participants must not be concurrently taking other medications or supplements with known hormonal effects, including PC-SPES, megestrol acetate, finasteride, ketoconazole, estradiol, or Saw Palmetto. All other medications with possible anti-cancer effects must be discussed with the PI prior to study entry.
  • Participants previously treated with other potential or experimental therapies for prostate cancer must have discontinued these treatments and completed at least a 4 week washout prior to beginning treatment.
  • Participants must not have known psychological or sociological conditions, addictive disorders or family problems, which would preclude compliance with the protocol.
  • Participants with unstable or severe intercurrent medical conditions or laboratory abnormalities that would impart, in the judgment of the PI, excess risk associated with study participation or study agent administration.
  • Participants who have concurrent enrollment on other phase I, II, or III investigational therapeutic treatment studies for prostate cancer cannot be actively receiving treatment and the last dose cannot be within 4 weeks of day 1. They must be in the follow up phase of the study.

Study Design

Enrollment

14 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Participants with non-castrate, recurrent, oligometastatic prostate cancer

Participants will receive a combination of vaccine and immunotherapy.

Interventions

pTVG-HP DNA vaccine

The vaccine will be injected into the outer side of the upper area of the arm in two adjacent sites, with 0.25 mL administered at each site.

Anti-PD-1 monoclonal antibody

Nivolumab is a potent human immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Participants will receive two 10mg doses.

Primary outcome measure

  • PSA (prostate-specific antigen) complete response rate [ Time Frame: 12 months ]
  • Incidence of Adverse Events [ Time Frame: 5 years ]
  • Toxicity Rates [ Time Frame: 5 years ]

Central Contacts and Locations

Central contacts

Cancer Connect

800-622-8922clinicaltrials@cancer.wisc.edu

Locations

University of Wisconsin - Madison

Recruiting

Madison, Wisconsin, United States, 53705

Contacts

Cancer Connect

800-622-8922clinicaltrials@cancer.wisc.edu

Principal Investigator:

John Floberg, MD, PhD

More Information

Sponsor

University of Wisconsin, Madison

Last update posted

Mar 11, 2026

Last verified

Mar, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by University of Wisconsin, Madison on 2026-03-11.